In a two-week double-blind, placebo-controlled trial, individuals taking ME-3 achieved reductions in oxidized LDL-cholesterol (71 U/l to 63 U/l), BDC-LDL (23.8 umol/l to 22.0 umol/l), and triglycerides (2.1 mmol/l to 1.9 mmol/l) and beneficial increases in PON (110.0 U/l to 133.4 U/l) and HDL-cholesterol (1.4 mmol/l to 1.5 mmol/l)
After binding of antigen to membrane-bound IgE via Fc-epsilon-RI receptors, they release histamine, platelet activating factor (PAF) and leukotrienes, and other inflammatory mediators
it is not suitable for use in diagnostic procedures without further evaluation.
Increased circulating RANTES in type 2 diabetes
Some agents (Wegovy, Saxenda) are also approved for weight management in adolescents aged 12 and older
However, understanding your individual metabolic profile and genetic predispositions to GLP-1 response can help you and your provider determine whether dual therapy or optimized single-agent treatment aligns with your health goals and safety baseline